Application | Comment | Organism |
---|---|---|
drug development | cathepsin B is a target for anti-cancer therapy. RNA interference oligonucleotide shRNA-CTSB2 is the most efficient inhibition of cathepsin B at both mRNA and protein levels and results in suppressing endometrial cancer growth and development in vivo | Homo sapiens |
medicine | cathepsin B is a target for anti-cancer therapy. RNA interference oligonucleotide shRNA-CTSB2 is the most efficient inhibition of cathepsin B at both mRNA and protein levels and results in suppressing endometrial cancer growth and development in vivo | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-(N-benzyloxycarbonylphenylalanylamido)-DL-1-fluoro-2-butanone | irreversible covalent inhibitor | Homo sapiens | |
ankyrin repeat protein | i.e. DARPin 8h6 | Homo sapiens | |
benzyloxycarbonyl-L-phenylalanyl-L-phenylalanyl diazomethyl ketone | irreversible covalent inhibitor | Homo sapiens | |
benzyloxycarbonyl-phenylalanyl diazomethyl ketone | irreversible covalent inhibitor | Homo sapiens | |
Bz-Phe-Arg-CH2F | irreversible covalent inhibitor | Homo sapiens | |
CA-074 | i.-e. [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline and its derivates, irreversible covalent inhibitor | Homo sapiens | |
E-64 | irreversible covalent inhibitor | Homo sapiens | |
E64d | i.e. loxistatin, irreversible covalent inhibitor | Homo sapiens | |
Miraziridine A | irreversible covalent inhibitor | Homo sapiens | |
additional information | concanamycin A is an indirect inhibitor by specific inhibiton of VATPase | Homo sapiens | |
N-Acetyl-Leu-Leu-methional | reversible inhibitor | Homo sapiens | |
peptidyl cyclopropenone | reversible inhibitor | Homo sapiens | |
RNA interference oligonucleotide shRNA-CTSB2 | most efficient inhibition of cathepsin B at both mRNA and protein levels and results in suppressing endometrial cancer growth and development in vivo | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cytoplasm | - |
Homo sapiens | 5737 | - |
lysosome | stress stimulated secretion from the lysosomes | Homo sapiens | 5764 | - |
mitochondrion | - |
Homo sapiens | 5739 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P07858 | - |
- |
Posttranslational Modification | Comment | Organism |
---|---|---|
proteolytic modification | cathepsin B is first expressed as a 44 kDa inactive precursor which then undergoes maturation to produce a 33 kDa lysosome enzyme later converted to a final active form composed of two (24 and 5 kDa) subunits | Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
breast cancer cell | - |
Homo sapiens | - |
chondrocyte | - |
Homo sapiens | - |
colonic adenocarcinoma cell | - |
Homo sapiens | - |
melanoma cell | - |
Homo sapiens | - |
rheumatoid arthritis disease specific synovial tissue | - |
Homo sapiens | - |
T/C-28a2 cell | - |
Homo sapiens | - |
General Information | Comment | Organism |
---|---|---|
physiological function | the main functions are the turnover of cellular proteins, the regulation of angiogenesis, invasion, tumor proliferation and immune resistance, neurogenesis, cellular differentiation and tumor response to hypoxia. Cathepsin B plays a protective role by degrading excessive amounts of misfolded protein inside the cell. In humans, the levels of cathepsin B correlates with hippocampal-dependent memory functions and can be increased by physical exercise. The decrease in the rate of neurogenesis in Alzheimer's disease can be secondary to the accumulation of the critical Alzheimer's disease proteins, which can be induced by inhibition of cathepsin B and the consequent the lysosomal dysfunction. The expression of cathepsin B is elevated in many, but not all, cancers | Homo sapiens |